請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56806
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 方俊民(Jim-Min Fang) | |
dc.contributor.author | Nien-Chia Lee | en |
dc.contributor.author | 李年加 | zh_TW |
dc.date.accessioned | 2021-06-16T05:49:38Z | - |
dc.date.available | 2019-09-04 | |
dc.date.copyright | 2014-09-04 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-08-08 | |
dc.identifier.citation | 1. De Clerq, E. Nat. Rev. Drug discov. 2006, 5, 1015–1025. Antiviral agents active against influenza A viruses.
2. Suzuki, Y. Biol. Pharm. Bull. 2005, 28, 399–408 Sialobiology of influenza molecular mechanism of host range variation of influenza viruses. 3. Horimoto, T.; Kawaoka, Y. Nat. Rev. Microbiol. 2005, 3, 591–600. Influenza: lessons from past pandemics, warnings from current incidents. 4. von Itzstein, M. Nat. Rev. Drug Discov. 2007, 6, 967–974. The war against influenza: discovery and development of sialidase inhibitors. 5. Das, K.; Aramini, J. M.; Ma, L.-C.; Krug, R. M.; Arnold, E. Nat. Struct. Mol. Biol. 2010, 17, 530–538. Structures of influenza A proteins and insights into antiviral drug targets. 6. Wilson, I. A.; Skehel, J. J.; Wiley, D. C. Nature 1981, 289, 366–373. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. 7. Weis, W.; Brown, J. H.; Cusack, S.; Paulson, J. C.; Skehel, J. J.; Wiley, D. C. Nature 1988, 333, 426–431. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. 8. Varghese, J. N.; Laver, W. G.; Colman, P. M. Nature 1983, 303, 35–40. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. 9a. Holsinger, L. J.; Nichani, D.; Pinto, L. H.; Lamb. R. A. J. Virol. 1994, 68, 1551–1563. Influenza A virus M2 ion channel protein: A structure–function analysis. 9b. Kozakov, D.; Chuang, G. Y.; Beglov, D.; Vajda, S. Trends Biochem. Sci. 2010, 35, 471–475. Where does amantadine bind to the influenza virus M2 proton channel? 10. Schnell, J. R.; Chou, J. J. Nature 2008, 451, 591–595. Structure and mechanism of the M2 proton channel of influenza A virus. 11. Davies, W. L.; Grunert, R. R.; Haff, R. F.; McGahen, J. W.; Neumayer, E. M.; Paulshock, M.; Watts, J. C.; Wood, T. R.; Hermann, E. C.; Hoffmann, C. E. Science 1964, 144, 862–863. Antiviral activity of 1-adamantanamine (amantadine). 12a. Bright, R. A.; Medina, M.-j.; Xu, X.; Perez-Oronoz, G.; Wallis, T. R.; Davis, X. M.; Povinelli, L.; Cox, N. J.; Klimov, A. I. The Lancet 2005, 366, 1175–1181. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. 12b. Bright, R. A.; Shay, D. K.; Shu, B.; Cox, N. J.; Klimov, A. I. J. Am. Med. Assoc. 2006, 295, 891–894. Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. 13a. Bodian, D. L.’ Yamasaki, R. B.; Buswell, R. L.; Stearns, J. F.; White, J. M.; Kuntz, I. D. Biochemistry 1993, 32, 2967–2978. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. 13b. Hoffman, L.; Kuntz, I.; White, J. J. Virol. 1997, 71, 8808–8820. Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity. 14. Russell, R. J.; Kerry, P. S.; Stevens, D. J.; Steinhauer, D. A.; Martin, S. R.; Gamblin, S. J.; Skehel, J. J. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 17736–17741. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. 15. Meindl, P.; Bodo, G.; Palese, P.; Schulman, J.; Tuppy, H. Virology 1974, 58, 457–463. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. 16. Von Itzestein, M.; Wu, W.-Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Phan, T. V.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R. C.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. Nature 1993, 363, 418– 423. Rational design of potent sialidase-based inhibitors of influenza virus replication. 17. Bossart-Whitaker, P.; Carson, M.; Babu, T. S.; Smith, C. D.; Laver, W. G.; Air, G. M. J. Molec. Biol. 1993, 232, 1069–1083. Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. 18. Holzer, C. T.; von Itzestein, M.; Jin, B.; Pegg, M. S.; Stewart, W. P.; Wu, W.-Y. Glycoconj. J. 1993, 10, 40–44. Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position. 19. Woods, J. M.; Bethell, R. C.; Coates, J. A.; Healy, N.; Hiscox, S. A.; Pearson, B. A.; Ryan, D. M.; Ticehurst, J.; Tilling, J.; Walcott, S. M. Antimicrob. Agents Chemother. 1993, 37, 1473–1479. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. 20. Andrews, D. M.; Cherry, P. C.; Humber, D. C.; Jones, P. S.; Keeling, S. P.; Martin, P. F.; Shaw, C, D.; Swanson, S. Eur. J. Med. Chem. 1999, 34, 563–574. Synthesis and influenza virus sialidase inhibitory activity of analogues of 4-guanidino-Neu5Ac2en (zanamivir) modified in the glycerol side-chain. 21. Honda, T.; Masuda, T.; Yoshida, S.; Arai, M.; Kaneko, S.; Yamashita, M. Bioorg. Med. Chem. Lett. 2002, 12, 1921–1924. Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives. 22. Honda, T.; Masuda, T.; Yoshida, S.; Arai, M.; Kaneko, S.; Yamashita, M. Bioorg. Med. Chem. Lett. 2002, 12, 1925–1928. Synthesis and anti-Influenza virus activity of 7-O-Alkylated derivatives related to zanamivir. 23. Liu, Z.-y.; Wang, B.; Zhao, L.-x.; Li, Y.-h.; Shao, H.-y.; Yi, H.; You, X.-f.; Li, Z.-r. Bioorg. Med. Chem. Lett. 2007, 17, 4851–4854. Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir). 24a. Yamashita, M. Int. Congr. Ser. 2004, 1263, 38–42. R-118958, a unique anti-influenza agent showing high efficacy for both prophylaxis and treatment after a single administration: from the in vitro stage to phase I study. 24b. Honda, T.; Kubo, S.; Masuda, T.; Arai, M.; Kobayashi, Y.; Yamashita, M. Bioorg. Med. Chem. Lett. 2009, 19, 2938–2940. Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methylNeu5Ac2en. 25. Ishizuka, H.; Yoshiba, S.; Okabe, H.; Yoshihara, K. J. Clin. Pharmacol. 2010, 50, 1319–1329. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. 26. Mammen, M.; Choi, S.-K.; Whitesides, G. M. Angew. Chem. Int. Ed. 1998, 37, 2754– 2794. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. 27. Watson, K. G.; Cameron, R.; Fenton, R. J.; Gower, D.; Hamilton, S.; Jin, B.; Krippner, G. Y.; Luttick, A.; McConnell, D.; MacDonald, S. J. F.; Mason, A. M.; Nguyen, V.; Tucker, S. P.; Wu, W.-Y. Bioorg. Med. Chem. Lett. 2004, 14, 1589– 1592. Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase. 28. Macdonald, S. J. F.; Wstson, K. G.; Cameron, R.; Chalmers, D. K.; Demaine, D. A.; Fenton, R. J.; Gower, D.; Hamblin, J. N.; Hamilton, S.; Hart, G. J.; Inglis, G. G. A.; Jin, B.; Jones, H. T.; McConnell, D. B.; Mason, A. M.; Nguyen, V.; Owens, I. J.; Parry, N.; Reece, P. A.; Shanahan, S. E.; Smith, D.; Wu, W.-Y.; Tucker, S. P. Antimicrob. Agents Chemother. 2004, 48, 4542–4549. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. 29. Kim, C. U.; Lew, W.; Williams, M. A.; Liu, H.; Zhang, L.; Swaminathan, S.; Bischofberger, N.; Chen, M. S.; Mendel, D. B.; Tai, C. Y.; Laver, W. G.; Stevens, R. S. J. Am. Chem. Soc. 1997, 119, 681–690. Influenza Neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. 30. Kim, C. U.; Lew, W.; Williams, M. A.; Wu, H.; Zhang, L.; Chen, X.; Escarpe, P. A.; Mendel, D. B.; Laver, W. G.; Stevens, R. C. J. Med. Chem. 1998, 41, 2451–2460. Structure−activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. 31a. Li, W.; Escarpe, P. A.; Eisenberg, E. J.; Cundy, K. C.; Sweet, C.; Jakeman, K. J.; Merson, J.; Lew, W.; Williams, M.; Zhang, L.; Kim, C. U.; Bischofberger, N.; Chen, M. S.; Mendel, D. B. Antimicrob. Agents Chemother. 1998, 42, 647–653. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. 31b. Sidwell, R. W.; Huffman, J. H.; Barnard, D. L.; Bailey, K. W.; Wong, M. H.; Morrison, A.; Syndergaard, T.; Kim, C. U. Antiviral Res. 1998, 37, 107–120. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. 32. McCullers, J. A. Expert Opin. Invest. Drugs 2005, 14, 305–312. Antiviral therapy of influenza. 33a. Russell, R. J.; Haire, L. F.; Stevens, D. J.; Collins, P. J.; Lin, Y. P.; Blackburn, G. M.; Hay, A. J.; Gamblin, S. J.; Skehel, J. J. Nature 2006, 443, 45–49. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. 33b. Collins,P.J.;Haire,L.F.;Lin,Y.P.;Liu,J.F.;Russell,R.J.;Walker,P.A.;Skehel, J. J.; Martin, S. R.; Hay, A. J.; Gamblin, S. J. Nature 2008, 453, 1258–1261. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. 34. Shie, J. J.; Fang, J. M.; Wang, S. Y.; Tsai, K. C.; Cheng, Y. S. E.; Yang, A. S.; Hsiao, S. C.; Su, C. Y.; Wong, C. H. J. Am. Chem. Soc. 2007, 129, 11892–11893. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity. 35. Yamamoto, T.; Kumazawa, H.; Inami, K.; Teshima, T.; Shiba, T. Tetrahedron Lett. 1992, 33, 5791–5794. Syntheses of sialic acid isomers with inhibitory activity against neuraminidase. 36. Babu, Y. S.; Chand, P.; Bantia, S.; Kotian, P.; Dehghani, A.; El-Kattan, Y.; Lin, T.-H.; Hutchison, T. L.; Elliott, A. J.; Parker, C. D.; Ananth, S. L.; Horn, L. L.; Laver, G. W.; Montgomery, J. A. J. Med. Chem. 2000, 43, 3482–3486. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. 37a. Vane, J. R. J. Physiol. Pharmacol. 2000, 51, 573–586. The fight against rheumatism: from willow bark to COX-1 sparing drugs. 37b. Rao, P. P. N.; Kabir, S. N.; Mohamed, T. Pharmaceuticals 2010, 3, 1530–1549. Nonsteroidal anti-inflammatory drugs (NSAIDs): progress in small molecule drug development. 38a. Vane, J. R. Nat. New Biol. 1971, 231, 232–235. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. 38b. Smith, J. B.; Willis A. L. Nat. New Biol. 1971, 231, 235–237. Aspirin selectively inhibits prostaglandin production in human platelets. 39a. Vane, J. R.; Botting, R. M. Thromb. Res. 2003, 110, 255–258. The mechanism of action of aspirin. 39b. Rosen, G. D.; Birkenmeier, T. M.; Raz, A.; Holtzman, M. J. Biochemical and Biophysical Research Comminications 1989, 164, 1358–1365. Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation. 40. Mitchell, J. A.; Akarasereenont, P.; Thiemermann, C.; Flower, R. J.; Vane, J. R. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 11693–11697. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. 41. Luong, C.; Miller, A.; Barnett, J.; Chow, J.; Ramesha, C.; Browner, M. F. Nat. Struct. Mol. Biol. 1996, 3, 927–933. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. 42. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Iyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Nature 1996, 384, 644–648. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. 43. Trelle, S.; Reichenbach, S.; Wandelm, S.; Hildebrand, P.; Tschannen, B.; Villiger, P. M.; Egger, M.; Juni, P. BMJ 2011, 342, c7087. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. 44. Adams, S. S. J. Clin. Pharmacol. 1992, 32, 317 BMJ 2011, 342, 317–323. The propionic acids: a personal perspective. 45. Chiang, Y. M.; Lo, C. P.; Che, Y. P.; Wang, S. Y.; Yang, N. S.; Kuo, Y. H.; Shyur, L. F. Br. J. Pharmacol. 2005, 146, 352–363. Ethyl caffeate suppresses NF-κB activation and its downstream inflammatory mediators, iNOS, COX-2, and PGE2in vitro or in mouse skin. 46a. Lu, F. J.; Tseng, S. N.; Li, M. L.; Shih, S. R. Arch. Virol. 2002, 147, 273–284. In vitro anti-influenza virus activity of synthetic humate analogues derived from protocatechuic acid. 46b. Sokmen, M.; Angelova, M.; Krumova, E.; Pashova, S.; Ivancheva, S.; Sokmen, A.; Serkedjieva, J. Life Sci. 2005, 76, 2981–2993. In vitro antioxidant activity of polyphenol extracts with antiviral properties from Geranium sanguineum L. 47. Gupta, G. P.; Nguyen, D. X.; Chiang, A. C.; Bos, P. D.; Kim, J. Y.; Nadal, C.; Gomis, R. R.; Manova-Todorova, K.; Massague, J. Nature 2007, 446, 765–772. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. 48a. Morphy, R.; Rankovic, Z. J. Med. Chem. 2006, 49, 4961–4970. The physicochemical challenges of designing multiple ligands. 48b. Morphy, R.; Kay, C.; Rankovic, Z. Drug Discov. Today 2004, 9, 641–651. From magic bullets to designed multiple ligands. 49. Lolli, M. L.; Cena, C.; Medana, C.; Lazzarato, L.; Morini, G.; Coruzzi, G.; Manarini, S.; Fruttero, R.; Gasco, A. J. Med. Chem. 2001, 44, 3463–3468. A new class of ibuprofen derivatives with reduced gastrotoxicity. 50. Murugesan, N.; Tellew, J. E.; Gu, Z.; Kunst, B. L.; Fadnis, L.; Cornelius, L. A.; Baska, R. A. F.; Yang, Y.; Beyer, S. M.; Monshizadegan, H.; Dickinson, K. E.; Panchal, B.; Valentine, M. T.; Chong, S.; Morrison, R. A.; Carlson, K. E.; Powell, J. R.; Moreland, S.; Barrish, J. C.; Kowala, M. C.; Macor, J. E. J. Med. Chem. 2002, 45, 3829–3835. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. 51. Barbey, S.; Goossens, L.; Taverne, T.; Cornet, J.; Choesmel, V.; Rouaud, C.; Gimeno, G.; Yannic-Arnoult, S.; Michaux, C.; Charlier, C.; Houssin, R.; Henichart, J. P. Bioorg. Med. Chem. Lett. 2002, 12, 779–782. Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor. 52. Govorkova, E. A.; Wgbster, R. G. Viruses 2010, 2, 1510–1529. Combination chemotherapy for influenza. 53. Lee, S. M. Y.; Cheung, C. Y.; Nicholls, J. M.; Hui, K. P. Y.; Leung, C. Y. H.; Uiprasertkul, M.; Tipoe, G. L.; Lau, Y. L.; Poon, L. L. M.; Ip, N. Y.; Guan, Y.; Peiris, J. S. M. J. Infect. Dis. 2008, 198, 525–535. Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection. 54. Ottolimi, M.; Blanco, J.; Porter, D.; Peterson, L.; Curtis, S.; Prince, G. Pediatr. Pulmonol. 2003, 36, 290–294. Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model. 55a. Chandler, M.; Bamford, M. J.; Conroy, R.; Lamont, B.; Patal, B.; Patel, V. K.; Steeeples, I. P.; Storer, R.; Weir, N. G.; Wright, M.; Williamson, C. J. Chem. Soc., Perkin Trans. 1 1995, 1173–1180. Synthesis of the potent influenza neuraminidase inhibitor 4-guanidino Neu5Ac2en. X-Ray molecular structure of 5-acetamido-4-amino-2,6-anhydro-3,4,5-trideoxy-D-erythro-L-gluco-nononic acid. 55b. Kok, G. B.; Groves, D. R.; von Itzstein, M. Chem. Commun. 1996, 2017–2018. A facile and direct entry to functionalised Neu5Ac2En derivatives from the methyl ketoside of Neu5Ac methyl esters. 55c. Kok, G. B.; Groves, D.; von Itzstein, M. J. Chem. Soc., Perkin Trans. 1 1999, 2109– 2215. A facile synthesis of Neu5Ac2en derivatives from the glycolsides of N-acetylneuraminic acid. 55d. Ying, L. Q.; Gervay-Hague, J. ChemBioChem 2005, 6, 1857–1865. One-bead-one- inhibitor-one-substrate screening of neuraminidase activity. 56. Wen, W.-H.; Lin, M.; Su, C.-Y.; Wang, S.-Y.; Cheng, T.-S. E.; Fang, J.-M.; Wong, C.-H. J. Med. Chem. 2009, 52, 4903–4910. Synergistic effect of zanamivir−porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus. 57. Zheng, B. J.; Chan, K. W.; Lin, Y. P.; Zhao, G. Y.; Chan, C.; Zhang, H. J.; Chen, H. L.; Wong, S. S.; Lau, S. K.; Woo, P. C.; Chan, K. H.; Jin, D. Y.; Yuen, K. Y. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 8096–8096. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. 58. Meunier, B. Acc. Chem. Res. 2008, 41, 69–77. Hybrid molecules with a dual mode of action: dream or reality? 59. Taylor, N. R.; von Itzestein, M. J. Med. Chem. 1994, 37, 616–624. Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. 60a. Wu, Y.; Wu, Y.; Tefsen, B.; Shi, Y.; Gao, G. F. Trends Microbiol. 2014, 22, 183–191. Bat-derived influenza-like viruses H17N10 and H18N11. 60b. Tong, S.; Zhu, X.; Li, Y.; Shi, M.; Zhang, J.; Bourgeois, M.; Yang, H.; Chen, X.; Recuenco, S.; Gomez, J.; Chen, L.-M.; Johnson, A.; Tao, Y.; Dreyfus, C.; Yu, W.; McBride, R.; Carney, P. J.; Gilbert, A. T.; Chang, J.; Guo, Z.; Davis, C. T.; Paulson, J. C.; Stevens, J.; Rupprecht, C. E.; Holmes, E. C.; Wilson, I. A.; Donis, R. O. PLoS Pathog. 2013, 9, e1003657. New world bats harbor diverse influenza A viruses. 61. Proudfoot, J. R. Bioorg. Med. Chem. Lett. 2005, 15, 1087–1090. The evolution of synthetic oral drug properties. 62. Zlatopolskiy, B. D.; Radzom, M.; Zeeck, A.; de Meijere, A. Eur. J. Org. Chem. 2006, 6, 1525–1534. Synthesis and precursor-directed biosynthesis of new hormaomycin analogues. 63. Yamashita, M.; Tomozawa, T.; Kakuta, M.; Tokumitsu, A.; Nasu, H.; Kubo, S. Antimicrob. Agents Chemother. 2009, 53, 186–192. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. 64. Liu, K.-C.; Fang, J.-M.; Jan, J.-T.; Cheng, T.-J. R.; Wang, S.-Y.; Yang, S.-T.; Cheng, Y.-S. E.; Wong, C.-H.; J. Med. Chem. 2012, 55, 8493–8501. Enhanced anti-influenza agents conjugated with anti-inflammatory activity. 65. 柳公正,瑞樂沙共軛衍生物對流感病毒之雙標靶治療:台灣大學化學系博士論文,2011. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56806 | - |
dc.description.abstract | 流行性感冒是一種嚴重的急性呼吸道感染,對於人類健康會有很嚴重的威脅,其病毒可以經由飛沫或是生物之間的接觸作為傳染途徑,而曾經在世界各地爆發的流感H5N1以及 H1N1,都可能再次造成大規模的流行,為了避免流感再次發生,開發和改良藥物是有其必要性。而瑞樂沙及克流感是現今治療流行性感冒感染的藥物之一,它們可以阻斷病毒表面一種由糖蛋白組成的神經胺酸酶,藉著來抑制病毒離去宿主細胞,避免再去感染周圍的細胞。然而,瑞樂沙進入人體中,能被生物吸收的效率太差, 導致它只能透過鼻腔吸入的方式進入人體;而克流感雖然抑制效果優於瑞樂沙,但在結構上的特異性因素,病毒經過多次突變後,對克流感的抗藥性會隨之增加,使得克流感抑制效果有逐漸轉弱的趨勢。
此外,流行性感冒通常會伴隨發炎的反應,因此,我們發展一種新型的雙效藥物,以瑞樂沙當做藥物基礎,試著開發瑞樂沙和抗發炎藥物的共軛型式,選擇三種含有較高脂溶性的抗發炎藥物(萘普生、布洛芬、咖啡酸),去與原來的瑞樂沙C9上做連接,並且藉由瑞樂沙對流感病毒的NA辨識能力,能將藥物集中在受病毒感染的組織周圍,藉此提高抗發炎的選擇性,預期能提高藥物在生物體中作用的時間。 利用本實驗室所開發出瑞樂沙的合成方法,先合成中間體22,再進一步成功合成出前軀藥物37系列,並針對結構上的修飾,進一步得到甲基酯衍生物41,將這些衍生物進行抗流感的活性測試,結果顯示衍生物37a和37b皆有不錯的抗NA抑制效果;比較令人訝異的是,咖啡酸衍生藥物37c和41c在初期NA抑制活性上, 顯示幾乎沒抑制活性;而甲基酯衍生物41c,在透過酵素水解甲基酯後,能回復抑 制病毒的效果(EC50 = 128 nM)。 期望這種雙功能性的前軀藥物能在進入人體細胞經由酵素水解來釋放瑞樂沙和抗發炎藥物進一步來抑制病毒的活性,未來仍須透過小鼠生物實驗來做進一步的驗證。 | zh_TW |
dc.description.abstract | Influenza is a severe health problem by causing serious acute respiratory infection. Influenza viruses can be spread by infectious droplet or creature’s interaction. The worldwide spread of the H5N1 flu and H1N1 flu may break out once more. To avoid the potential menace, designing and synthesizing new drugs have come to be recent trends. Zanamivir is one of the effective drugs for the treatment of influenza infections. They can block influenza virus neuraminidase, a glycoprotein on virus surface, to prevent virus from leaving host cell to infect surrounding cells. However, zanamivir must be administered by inhalation due to its poor bioavailability after transmitted into body.
Influenza infection is usually accompanied by inflammation. Hence, we design a new type of dual-target conjugates of zanamivir with anti-inflammatory drug. We choose three anti-inflammatory drugs with good lipophilicity, including naproxen, ibuprofen and caffeic acid, to link with zanamivir at the C9 position. The moiety of zanamivir acted as a recognition unit that brought the anti-inflammatory moiety to the damaged tissue to suppress the cytokines caused by influenza virus. The prodrug is also expected to work as a long-acting neuraminidase inhibitor. In this study, we developed the zanamivir derivatives 37 through an intermediate compound 22, and further modified the C1 carboxylic acid to afford the methyl ester derivatives 41 as potential prodrugs. The results showed that the derivatives 37a and 37b had good NA inhibition. Unexpectedly, the preliminary test showed that the caffeic acid derivatives 37c and 41c had nearly no inhibition. Our cell-based assay indicated that methyl ester 41c resumed anti-influenza activity with EC50 = 128 nM. The dual functional prodrugs are expected to undergo endogenous enzymatic hydrolysis in body to give the parental zanamivir and anti-inflammatory drugs, which may show synergistic effect in inhibition of influenza virus. Mice experiments are necessary in the future. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T05:49:38Z (GMT). No. of bitstreams: 1 ntu-103-R01223128-1.pdf: 20099831 bytes, checksum: 61bb3d2cc2722dbc94b6b6f35bf79e77 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 中文摘要................................................................................... i Abstract................................................................................... iii
目錄......................................................................................... v 表目錄...................................................................................... viii 圖目錄...................................................................................... ix 流程目錄................................................................................... x 簡稱用語對照表......................................................................... xi 第一章 緒論 ............................................................................. 1 第一節 流行性感冒與人類....................................................... 1 第二節 流感病毒簡介............................................................. 3 2-1 流行性感冒病毒之組成................................................ 3 2-2 流行性感冒病毒之生命週期(life cycle).......................... 5 2-3 流行性感冒病毒其表面兩種重要的膜蛋白....................... 6 2-3-1 血球凝集素(hemagglutinin,HA) ......................... 6 2-3-2 神經胺酸酶(neuraminidase,NA) ......................... 8 2-4 離子通道蛋白 M2(M2 ion-channel)............................. 9 第三節 流感藥物的開發.......................................................... 10 3-1 離子通道蛋白 M2 抑制劑(M2 ion channel inhibitor)..... 10 3-2 血球凝集素之抑制劑(hemagglutinin inhibitor)............. 11 3-3 神經胺酸酶之抑制劑(neuraminidase inhibitor) ............ 11 3-3-1 瑞樂沙(zanamivir)的開發.................................... 13 3-3-2 Zanamivir 的修飾以及改進 ................................. 15 3-3-3 多價型化合物 .................................................... 16 3-3-4 Oseltamivir 的發展............................................ 18 3-3-5 神經胺酸酶抗藥性的問題..................................... 21 3-3-6 零流感(Tamiphosphor)的發展............................. 22 3-3-7 Peramivir 的開發............................................... 23 第四節 發炎(inflammation)反應及其藥物 ............................... 24 4-1 具有選擇性的抗發炎藥物............................................. 25 4-2 萘普生(naproxen)與布洛芬(ibuprofen)........................ 26 4-3 咖啡酸(caffeic acid)與抗發炎...................................... 26 第五節 多標靶藥物治療(multi-target therapy)........................ 27 第六節 抗流感以及抗發炎合併治療.......................................... 29 第二章 結果與討論 ................................................................... 31 第一節 Zanamivir 的合成...................................................... 31 第二節 設計雙標靶抗流感藥物................................................ 34 2-1 設計概念................................................................... 34 2-2 分配係數(partition coefficient)與分佈係數(distribution coefficient)之計 算............................................................................ 35 2-3 Zanamivir衍生物的合成............................................. 37 2-4 離體培養活性檢測..................................................... 47 2-4-1 抗流感活性測試................................................ 47 2-4-2 抗流感活性測試結果與討論................................ 48 2-5 結論....................................................................... 51 第三章 實驗部分..................................................................... 53 第一節 General Part........................................................... 53 第二節 Procedure of Bioassay............................................ 54 第三節 Synthetic Procedures and Characterization of Compounds......56 第四章 參考文獻.................................................................... 79 附錄 化合物之核磁共振光譜.................................................... 91 | |
dc.language.iso | zh-TW | |
dc.title | 合成含有較高生物利用度之雙效型瑞樂沙衍生抗流感藥物 | zh_TW |
dc.title | Design and Synthesis of Zanamivir Derivatives as Dual Functional Anti-influenza Drugs with Improved Bioavailability | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 吳世雄(Shih-Hsiung Wu),周必泰(Pi-Tai Chou),鄭偉杰(Wei-Chieh Cheng) | |
dc.subject.keyword | 瑞樂沙,流行性感冒,神經胺酸?,前軀藥物,抗發炎藥物, | zh_TW |
dc.subject.keyword | zanamivir,influenza,neuraminidase,prodrug,anti-inflammatory drug, | en |
dc.relation.page | 111 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-08-08 | |
dc.contributor.author-college | 理學院 | zh_TW |
dc.contributor.author-dept | 化學研究所 | zh_TW |
顯示於系所單位: | 化學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 19.63 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。